US 11,952,413 B2
Dimerizing agent regulated immunoreceptor complexes comprising interleukin receptor signaling domains
Wai-Hang Leung, Seattle, WA (US)
Assigned to 2SEVENTY BIO, INC., Cambridge, MA (US)
Appl. No. 16/771,402
Filed by 2seventy bio, Inc., Cambridge, MA (US)
PCT Filed Dec. 14, 2018, PCT No. PCT/US2018/065786
§ 371(c)(1), (2) Date Jun. 10, 2020,
PCT Pub. No. WO2019/118895, PCT Pub. Date Jun. 20, 2019.
Claims priority of provisional application 62/598,923, filed on Dec. 14, 2017.
Prior Publication US 2020/0392204 A1, Dec. 17, 2020
Int. Cl. C07K 14/54 (2006.01); A61K 35/17 (2015.01); A61K 38/00 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C07K 14/73 (2006.01)
CPC C07K 14/7155 (2013.01) [A61K 35/17 (2013.01); A61K 38/00 (2013.01); A61P 35/00 (2018.01); C07K 14/70514 (2013.01); C07K 14/70517 (2013.01); C07K 14/70575 (2013.01); C07K 2319/70 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A fusion polypeptide comprising:
(a) a first polypeptide comprising, in the following order:
(i) a first extracellular multimerization domain;
(ii) a first transmembrane domain; and
(iii) an IL-18R1 immune receptor intracellular signaling domain;
(b) a polypeptide cleavage signal; and
(c) a second polypeptide comprising, in the following order:
(i) a second extracellular multimerization domain;
(ii) a second transmembrane domain; and
(iii) an IL-18RAP immune receptor intracellular signaling domain;
wherein the first extracellular multimerization domain comprises an FKBP12-rapamycin binding (FRB) polypeptide and the second extracellular multimerization domain comprises an FK506 binding protein (FKBP12) polypeptide; or
wherein the first extracellular multimerization domain comprises an FKBP12 polypeptide and the second extracellular multimerization domain comprises an FRB polypeptide; and
wherein the fusion polypeptide has a sequence having at least 95% identity to SEQ ID NO: 5.